Nicaise Claude 4

4 · Chemomab Therapeutics Ltd. · Filed Mar 23, 2023

Form 4

Period: 2023-03-16

Director

Transactions

Award
Option to Purchase American Depositary Shares
2023-03-16+6,857→ 6,857 total
Exercise: $1.62Exp: 2033-03-21→ American Depositary Shares (6,857 underlying)
Award
Option to Purchase American Depositary Shares
2023-03-16+6,820→ 6,820 total
Exercise: $3.53Exp: 2032-03-07→ American Depositary Shares (6,820 underlying)
Award
Option to Purchase American Depositary Shares
2023-03-16+11,884→ 11,884 total
Exercise: $27.26Exp: 2031-04-19→ American Depositary Shares (11,884 underlying)

Footnotes (5)

[F1]These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
[F2]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
[F3]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
[F4]These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
[F5]These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

Documents

1 file